These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. MRI findings in pediatric neuromyelitis optica spectrum disorder with MOG antibody: Four cases and review of the literature. Ikeda A; Watanabe Y; Kaba H; Kaneko K; Takahashi T; Takeshita S Brain Dev; 2019 Apr; 41(4):367-372. PubMed ID: 30447856 [TBL] [Abstract][Full Text] [Related]
46. Myelitis in inflammatory disorders associated with myelin oligodendrocyte glycoprotein antibody and aquaporin-4 antibody: A comparative study in Chinese Han patients. ZhangBao J; Huang W; Zhou L; Wang L; Chang X; Lu C; Zhao C; Lu J; Quan C Eur J Neurol; 2021 Apr; 28(4):1308-1315. PubMed ID: 33220172 [TBL] [Abstract][Full Text] [Related]
47. [Clinical analysis of neuromyelitis optica spectrum disorders in childhood]. Zhou J; Zhang Y; Ji TY; Jin YW; Bao XH; Zhang YH; Xiong H; Chang XZ; Jiang YW; Wu Y Zhonghua Er Ke Za Zhi; 2019 Feb; 57(2):118-124. PubMed ID: 30695886 [No Abstract] [Full Text] [Related]
49. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. Kitley J; Waters P; Woodhall M; Leite MI; Murchison A; George J; Küker W; Chandratre S; Vincent A; Palace J JAMA Neurol; 2014 Mar; 71(3):276-83. PubMed ID: 24425068 [TBL] [Abstract][Full Text] [Related]
50. Retinal structural and microvascular changes in myelin oligodendrocyte glycoprotein antibody disease and neuromyelitis optica spectrum disorder: An OCT/OCTA study. Lang Y; Kwapong WR; Kong L; Shi Z; Wang X; Du Q; Wu B; Zhou H Front Immunol; 2023; 14():1029124. PubMed ID: 36793713 [TBL] [Abstract][Full Text] [Related]
51. Interleukin-33 as a Biomarker Affecting Intrathecal Synthesis of Immunoglobulin in Neuromyelitis Optica Spectrum Disorder and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. Wang M; Xia D; Sun L; Bi J; Xie K; Wang P Eur Neurol; 2023; 86(4):256-262. PubMed ID: 37100033 [TBL] [Abstract][Full Text] [Related]
52. Myelin oligodendrocyte glycoprotein antibody associated central nervous system demyelinating disease: a tertiary center experience from Turkey. Inan B; Gocmen R; Vural A; Colpak AI; Meinl E; Karabudak R; Tuncer A Mult Scler Relat Disord; 2020 Sep; 44():102376. PubMed ID: 32674059 [TBL] [Abstract][Full Text] [Related]
53. Relapse activity in the chronic phase of anti-myelin-oligodendrocyte glycoprotein antibody-associated disease. Akaishi T; Misu T; Fujihara K; Takahashi T; Takai Y; Nishiyama S; Kaneko K; Fujimori J; Ishii T; Aoki M; Nakashima I J Neurol; 2022 Jun; 269(6):3136-3146. PubMed ID: 34820735 [TBL] [Abstract][Full Text] [Related]
57. Comparative study of AQP4-NMOSD, MOGAD and seronegative NMOSD: a single-center Belgian cohort. Dauby S; Dive D; Lutteri L; Andris C; Hansen I; Maquet P; Lommers E Acta Neurol Belg; 2022 Feb; 122(1):135-144. PubMed ID: 34097296 [TBL] [Abstract][Full Text] [Related]
58. A systematic literature review to examine the considerations around pregnancy in women of child-bearing age with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) or aquaporin 4 neuromyelitis optica spectrum disorder (AQP4+ NMOSD). Leite MI; Panahloo Z; Harrison N; Palace J Mult Scler Relat Disord; 2023 Jul; 75():104760. PubMed ID: 37224631 [TBL] [Abstract][Full Text] [Related]
59. Clinical Characteristics and Treatment of MOG-IgG-Associated Optic Neuritis. Tajfirouz DA; Bhatti MT; Chen JJ Curr Neurol Neurosci Rep; 2019 Nov; 19(12):100. PubMed ID: 31773369 [TBL] [Abstract][Full Text] [Related]
60. Contrasting the brain imaging features of MOG-antibody disease, with AQP4-antibody NMOSD and multiple sclerosis. Messina S; Mariano R; Roca-Fernandez A; Cavey A; Jurynczyk M; Leite MI; Calabrese M; Jenkinson M; Palace J Mult Scler; 2022 Feb; 28(2):217-227. PubMed ID: 34048323 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]